Schedule 13D ownership disclosure
Juno Therapeutics, Inc.
Security class unavailable · CUSIP: 48205A109
Event date: 2017-03-24
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 9.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001571049-17-002901
- Form type
- SC 13D
- Filer
- Celgene Switzerland LLC
- CIK
- CIK 1661486
- Filed
- Mar 27, 2017
- Reporting period
- Mar 24, 2017
- Description
- Schedule 13D beneficial ownership